Please assess the completion status of the following clinical trial:

Trial Title: Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Any cachectic patient with weight loss presumed secondary to cancer or cancer related therapy is eligible. Cachexia is defined as having one or more of the following:~* documented history of weight loss \> 5%~* drop in growth rate two or more percentile ranks on standard growth charts,~* weight for height less than the tenth percentile.~* Patients with newly diagnosed or relapsed cancer of any type, including brain tumors.~* Patients who are receiving active or palliative therapy are eligible.~* If patients have completed treatment for cancer (surgery, chemotherapy, radiotherapy) within 8 weeks of study registration, they are also eligible.~* Patients must be ≥ 2 years and \< 21 years of age at the time of admission to this study.~* Patients must have a predicted life expectancy of at least eight weeks.~EXCLUSION CRITERIA:~* Patients who are currently taking or who have taken Periactin and/or Megace during the past three weeks are not eligible.~* Patients receiving corticosteroid or monoamine oxidase (MAO) inhibitor therapy. (Intermittent steroid use is permitted IF you anticipate it will not be administered for more than 7 days in a 4 week period. Calculate anticipated intermittent steroid use in 4-week intervals through the 8-week period during which study agent may be administered (4 weeks for Periactin and potentially 4 weeks for Megace.~* Patients who have received parenteral nutrition or tube feedings within 1 week of starting this protocol or patients who are expected to require parenteral nutrition or tube feedings during the 4-week course of this study.~* Patients taking dronabinol (Marinol) or other appetite-stimulating medications during the past three weeks or patients expected to be prescribed appetite-stimulating medications during the 4-week course of this study.~* Patients with hormone sensitive tumors specifically meningiomas, breast cancer, ovarian cancer, and endometrial carcinoma.31, 32~* Children with neurofibromatosis, type I or II, are at risk for the development of meningiomas and are thus excluded from this study.32~* Children with glaucoma, chronic persistent asthma, or gastrointestinal (GI) or genitourinary (GU) obstruction.~* Patients with recurrent and/or persistent hypertension, defined as blood pressure values \>20% above normal.~* Patients with thromboembolic disease, congestive heart failure, or peripheral edema.~* Patients who are pregnant.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Subjects that respond to Periactin (Type: EXPERIMENTAL): Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
- Non-responders to Periactin- Megace Arm (Type: EXPERIMENTAL): Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).